Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020.
Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. Mehta-Shah N, et al. Among authors: william bm. J Natl Compr Canc Netw. 2020 May;18(5):522-536. doi: 10.6004/jnccn.2020.0022. J Natl Compr Canc Netw. 2020. PMID: 32380458
Age is No Barrier: CAR-T Therapy in Older Adults.
Maakaron JE, William BM. Maakaron JE, et al. Among authors: william bm. Drugs Aging. 2023 Aug;40(8):685-689. doi: 10.1007/s40266-023-01047-z. Epub 2023 Jul 11. Drugs Aging. 2023. PMID: 37432595 Review.
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L. Hanel W, et al. Among authors: william bm. Cancers (Basel). 2023 Feb 24;15(5):1437. doi: 10.3390/cancers15051437. Cancers (Basel). 2023. PMID: 36900230 Free PMC article.
Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: william bm. Br J Haematol. 2016 May;173(3):404-12. doi: 10.1111/bjh.13975. Epub 2016 Mar 8. Br J Haematol. 2016. PMID: 26953041 Free article.
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: william bm. Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22. Br J Haematol. 2016. PMID: 27443247 Free article.
Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM. Starr AG, et al. Among authors: william bm. Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20. Hematology. 2017. PMID: 28105889
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018.
Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H. Horwitz SM, et al. Among authors: william b. J Natl Compr Canc Netw. 2018 Feb;16(2):123-135. doi: 10.6004/jnccn.2018.0007. J Natl Compr Canc Netw. 2018. PMID: 29439173
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, Whittaker S, Rotolo F, Ram-Wolff C, Khodadoust MS, Bensussan A, Paturel C, Bonnafous C, Sicard H, Azim HA Jr, Kim YH. Bagot M, et al. Among authors: william bm. Lancet Oncol. 2019 Aug;20(8):1160-1170. doi: 10.1016/S1470-2045(19)30320-1. Epub 2019 Jun 25. Lancet Oncol. 2019. PMID: 31253572 Clinical Trial.
82 results